3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
28
Nivolumab
14
Ipilimumab
7
Cyclophosphamide
7
spartalizumab
6
atezolizumab
4
Interleukin-2
4
fludarabine
3
durvalumab
3
cemiplimab
3
avelumab
3
aldesleukin
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Immune Checkpoint Inhibitors
3
Docetaxel
3
obinutuzumab
2
epacadostat
2
budigalimab
2
bempegaldesleukin
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Carboplatin
2
CTLA-4 Antigen
2
Biopsy
2
vocimagene amiretrorepvec
1
venetoclax
1
utomilumab
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts